Prudential Financial Inc Bridge Bio Pharma, Inc. Transaction History

Prudential Financial Inc

$70 Billion
Q3 2024

A detailed history of Prudential Financial Inc transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 13,789 shares of BBIO stock, worth $332,452. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,789

Previous 14,507 4.95%

Holding current value

$332,452

Previous $367,000 4.36%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$23.91 - $31.3 $17,167 - $22,473	-718 Reduced 4.95%	13,789 $351,000
Q2 2024 Aug 13, 2024	BUY	$23.0 - $31.04 $33,281 - $44,914	1,447 Added 11.08%	14,507 $367,000
Q1 2024 May 14, 2024	BUY	$27.35 - $40.45 $83,280 - $123,170	3,045 Added 30.4%	13,060 $403,000
Q4 2023 Feb 13, 2024	BUY	$24.02 - $43.89 $39,008 - $71,277	1,624 Added 19.35%	10,015 $404,000
Q3 2023 Nov 13, 2023	BUY	$16.89 - $35.01 $141,723 - $293,768	8,391 New	8,391 $221,000
Q1 2022 May 13, 2022	SELL	$7.34 - $17.16 $67,623 - $158,095	-9,213 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$11.38 - $53.41 $37,098 - $174,116	-3,260 Reduced 26.14%	9,213 $474,000
Q3 2021 Nov 15, 2021	BUY	$46.87 - $64.24 $19,310 - $26,466	412 Added 3.42%	12,473 $650,000
Q2 2021 Aug 16, 2021	SELL	$46.47 - $63.93 $2,044 - $2,812	-44 Reduced 0.36%	12,061 $736,000
Q1 2021 May 12, 2021	SELL	$55.47 - $72.35 $1.28 Million - $1.66 Million	-22,989 Reduced 65.51%	12,105 $746,000
Q4 2020 Feb 16, 2021	BUY	$38.38 - $71.11 $1.12 Million - $2.08 Million	29,284 Added 504.03%	35,094 $2.5 Million
Q3 2020 Nov 16, 2020	BUY	$27.2 - $42.19 $158,032 - $245,123	5,810 New	5,810 $218,000

Others Institutions Holding BBIO

# of Institutions

288

Shares Held

171M

Call Options Held

8.38M

Put Options Held

2.27M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.57B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Account

Prudential Financial Inc Bridge Bio Pharma, Inc. Transaction History